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Multiple sclerosis (MS) is a chronic and progressively debilitating disease of the central nervous system. Treatment
of MS involves disease-modifying therapies (DMTs) to reduce the incidence of relapses and prevent disease progression.
Glatiramer acetate (Copaxone®) was the first of the currently approved DMTs to be tested in human subjects, and it is
still considered a standard choice for first-line treatment. The mechanism of action of glatiramer acetate appears to be
relatively complex and has not been completely elucidated, but it is likely that it involves both immunomodulating and
neuroprotective properties. The efficacy of glatiramer acetate 20 mg/mL once daily as first-line treatment in relapsing-
remitting MS is well established, with ample evidence of efficacy from both placebo-controlled and active-comparator
controlled clinical trials as well as real-world studies. There is also a considerable body of evidence indicating that the
efficacy of glatiramer acetate is maintained in the long term. Clinical trial and real-world data have also consistently
shown glatiramer acetate to be safe and well tolerated. Notably, glatiramer acetate has a good safety profile in women
planning a pregnancy, and is not associated with foetal toxicity. Until recently, glatiramer acetate was only approved as
20 mg/mL once daily, but a new formulation with less frequent administration, 40 mg/mL three times weekly, has been
developed and is now approved in many countries, including Italy. This review examines the mechanism of action,
clinical efficacy, safety and tolerability of glatiramer acetate to provide suggestions for optimizing the use of this drug
in the current MS therapeutic scenario.
Keywords: Multiple sclerosis, Glatiramer acetate, Disease-modifying therapy, Pregnancy, Clinically isolated syndromeBackground
Multiple sclerosis (MS) is a chronic, progressively debili-
tating disease affecting the central nervous system (CNS).
It is characterised by multifocal inflammation leading to
demyelination, axonal damage and impaired nerve con-
duction; MS is usually thought to be an inflammatory,
immune-mediated condition in the relapsing phase, but in
the chronic progressive phase a neurodegenerative com-
ponent is predominant [1]. The definition of clinically iso-
lated syndrome (CIS) [2] is used to recognize the first
clinical presentation of a disease that could be MS, but
has yet to fulfil criteria of dissemination in time.* Correspondence: comi.giancarlo@hsr.it
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rently available to effectively treat MS, with the aim of
abolishing/reducing the number of relapses and prevent-
ing disease progression [3]. Due to the chronic nature of
the disease, when assessing/exploring the profile of a puta-
tive treatment both efficacy and safety have to be exam-
ined in the long term [4].
Glatiramer acetate (GA, Copaxone®) was the first of
the currently approved drugs to be tested in human sub-
jects with MS [5, 6]. However, the approval of GA by the
European Medicines Agency (EMA), at the dose of 20 mg/
mL once daily, subcutaneously administered, dates to
2001, when it joined interferon-beta (IFN-β) in the thera-
peutic armamentarium. The therapeutic indications are
the following: first-line treatment of ambulatory patients
with RRMS according to McDonald criteria and treatment
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osis (CDMS) [7].
Very recently, with the availability of a new GA formula-
tion (40 mg/mL, injected three times weekly), that was
demonstrated to be equally effective as the 20 mg/mL
once daily dose in patients with RRMS [8] and was ap-
proved both by the EMA and the Food and Drug Admin-
istration (FDA), a substantial gain in patients’ quality of
life has been achieved. The aim of this review is examining
the mechanism of action, clinical efficacy, safety and toler-
ability profiles of GA to provide suggestions for optimiz-
ing the use of this drug in the current MS therapeutic
scenario.Fig. 1 Immune-mediated pathological and modulatory pathways in multip
acetate (GA). GA has been shown to increase levels of neurotrophic factors
patients and whose actions include protection of neurons against pathologic
GA may promote neural growth and inhibit inflammatory demyelination resu
been shown to oppose glutamate excitotoxicity by restoring normal kinetic p
GA may produce this effect by blocking synaptic alterations due to TNF-alpha
interferon; IL, interleukin; MMP, matrix metalloproteinase; TGF, transforming gr
cell (Modified with permission from [11])Mechanism of action
The mechanism of action of GA in MS is complex, likely
involving an interplay of immunomodulating and neuro-
protective properties, with details still to be fully eluci-
dated [9–13] (Fig. 1).
GA was originally designed by researchers at the
Weizmann Institute in Israel as a synthetic analogue
of myelin basic protein (MBP, an autoantigen implicated
in the pathogenesis of MS), with the aim of using it as a
molecular mimic of MBP to study the biology of experi-
mental autoimmune encephalomyelitis (EAE), an animal
model of MS [14]. GA is a standardised mixture of poly-
peptides randomly polymerized from four L-amino acids,le sclerosis (MS) and possible neuroprotective actions of glatiramer
(a), which are reduced in the serum and the cerebrospinal fluid of MS
al insults. By inducing specific populations of Th2 cells in the periphery,
lting in loss of axons, neurons and oligodendrocytes (b). GA has also
roperties of glutamate-mediated synaptic transmission in the striatum (c).
released by activated microglia (d). APC, antigen presenting cell; IFN,
owth factor; Th, T helper; TNF, tumor necrosis factor; Treg, regulatory T
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defined molar residue ratio of 0.14:0.34:0.43:0.09. The
same ratio is found in the amino acid sequence of MBP.
The molecular mass of the constituent polypeptides of
GA ranges from 4.7 to 11 KDa.
The researchers found that, surprisingly, the synthe-
sised analogue did not induce EAE, but instead sup-
pressed its development after exposure to crude myelin
preparations [15]. This finding encouraged studies focus-
sing on potential competition between GA and MBP in
various immune cell-related events, especially in binding
to major histocompatibility complex (MHC) molecules
and T-cell antigen receptors [16, 17]. However, it should
be noted that these results were mostly obtained using
in vitro test systems, and their relevance to the mechan-
ism of action of GA in vivo is uncertain. Aharoni and
colleagues also reported that GA can block the prolifera-
tion of MBP-reactive T lymphocytes [18], but this find-
ing was not reliably reproduced in subsequent studies.
In fact, more recently, it has been shown that GA does
not alter the proliferation of MBP-reactive T cells, but
some GA-reactive T cells (specifically the Th2 cells) can
respond to MBP by secreting protective cytokines [19].
GA-specific T cells, being able to cross the blood-brain
barrier (while the drug itself is not) mediate the activity of
GA in the central nervous system (CNS). Moreover GA-
activated T cells are able to suppress EAE induced not
only by MBP, but also by other encephalitogens, such as
proteolipid protein (PLP) and myelin oligodendrocyte
glycoprotein (MOG): this so-called “bystander suppression
mechanism” is considered an essential component of the
mechanism of action of GA [20].
An important immunomodulatory effect of GA – and
possibly the primary mechanism behind its activity – is
the induction of a shift in the phenotype of reactive T cells
from a mostly pro-inflammatory Th1 pattern of cytokine
secretion to a mostly anti-inflammatory Th2 pattern in-
volving the production of IL-4, IL-5, IL-13, IL-10 and
TGF-β [19, 21–27]. However, even if this is probably the
most important mechanism of action of GA, other bio-
logical effects have been reported.
The role of Th17 cells (a subset of T cells that produce
a distinct profile of proinflammatory cytokines, including
interleukin [IL]-17, IL-6, IL-9, IL-21, IL-22, IL-23, IL-26
and tumour necrosis factor-α [TNF-α]) in the immuno-
pathogenesis of MS and EAE has recently been eluci-
dated [28–30]. GA was found to reduce Th-17-related
neuroinflammation and levels of IL-17 and IL-6 in EAE
mice [31, 32].
Studies have shown that, in addition to Th17 cells, GA
acts on regulatory T (Treg) cells, whose role in suppress-
ing autoimmunity is well recognized [33]. Patients with
RRMS have an impaired CD4+ CD25+ Treg cells-related
suppressive capacity [34], and functional alterations ofTreg cells in RRMS may be associated with decreased ex-
pression of scurfin, a product of the transcription factor
forkhead box P3 (Foxp3) [35]. GA can increase Foxp3 ex-
pression, and in vitro studies have shown that exposure of
peripheral CD4+ T cells from healthy humans or GA-
immunized mice to GA results in an increase in regula-
tory T cells, via activation of Foxp3 [36]. A similar finding
was reported in a small study in RRMS patients, in which
treatment with GA for up to 6 months increased total
Treg numbers and reversed the Treg defect [37].
Additionally, it has been demonstrated that GA may
act to cause a switch in the B cell phenotype of patients
with MS, leading to the development of low but signifi-
cant titres of GA-reactive IgG4 antibodies [38]. Because
the isotype switch to IgG4 in B cells requires IL-4, an
important anti-inflammatory cytokine, this finding fur-
ther supports the anti-inflammatory action of GA in
treated patients.
There is also evidence to suggest that GA, in addition
to its action on the adaptive immune system, acts on
the innate immune system by directly modulating the
activity of myeloid cells, in particular monocytes and
dendritic cells [39–42]. The properties of monocytes of
RRMS patients undergoing treatment with GA have
been compared with those of untreated patients and of
healthy controls, showing that monocyte reactivity was
inhibited in the treated patients. This study is import-
ant since it was the first to demonstrate this effect in
human subjects treated with GA [43].
A number of studies have also addressed the question of
the possible neuroprotective effects of GA. The results of
in vitro and animal model studies have shed some light on
the possible mechanisms of these effects. In addition to in-
ducing an anti-inflammatory milieu in the CNS through
the action of reactive T cells, GA has been shown to in-
crease levels of neurotrophic factors such as brain-derived
neurotrophic factor (BDNF), the actions of which include
protection of neurons against pathological insults [11, 44].
Another possible neuroprotective action of GA, against
glutamate excitotoxicity, was recently reported in a mouse
model of MS [45]: GA was found to restore normal kinetic
properties of glutamate-mediated synaptic transmission in
the striatum of treated animals, contrasting the excessive
glutamate action on postsynaptic receptors. GA produces
this effect (independently of its immunomodulatory ac-
tion) possibly by blocking synaptic alterations induced by
activated microglia-released TNF-α.
The induction of specific populations of Th2 cells in the
periphery by GA may lead to an environment favouring
axonal protection, neural growth and remyelination, as re-
ported in an in vitro and in vivo study by Skihar and col-
leagues [46]. Exposure of mouse embryonic forebrain cells
in culture to GA-reactive T cells resulted in increased
levels of insulin-like growth factor-1 (IGF-1) and promoted
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Subsequently, mice subjected to induced demyelination of
the spinal cord were treated with GA; after 7 days, in-
creased OPC generation and remyelination were observed,
associated with higher levels of IGF-1 and BDNF in the
spinal cord.
Some observations from clinical trials seem to support
such effects. In a substudy of the PreCISe trial, patients
treated with GA had increased brain concentrations of
the neuronal integrity marker N-acetylaspartate, and an
improvement in brain neuronaxonal integrity, whereas
patients receiving placebo did not [47]. Also, magnetic
resonance imaging (MRI) studies have demonstrated the
ability of GA to reduce the proportion of new T1 hypoin-
tense lesions evolving into permanent black holes (markers
of irreversible axonal loss), therefore supporting the neuro-
protective scenario [48, 49].
Clinical efficacy
Subcutaneous GA has a long history of use for the treat-
ment of RRMS. The initially approved dose, on the basis
of animal studies, is 20 mg/mL once daily; still widely con-
sidered as standard, it was a keystone for all later drug de-
velopment. Attempts to explore higher weekly doses (40
mg/mL once daily) showed no additive benefit [50, 51].
Recent results of the GALA study [8] indicate that main-
taining a similar weekly dose, but with a different dosing
regimen (40 mg/mL three times a week), provides advan-
tages in clinical use without impacting on efficacy.
The feasibility of oral administration of GA was tested
in the placebo-controlled CORAL trial [52]. Patients with
RRMS received 50 mg or 5 mg of GA or placebo daily for
14 months. Neither dose of GA affected the primary end-
point (relapse rate) or any other clinical and MRI end-
point. Thus, further development of oral administration
was discontinued. GA has been tested in progressive MS
with negative results.
Once-daily formulation
In relapsing-remitting multiple sclerosis
The efficacy of GA 20 mg/mL once daily as first-line
treatment in RRMS is well established in many phase II,
III and IV studies.
Placebo-controlled trials The efficacy of GA on clin-
ical and MRI-assessed outcomes has been demon-
strated in two major pivotal placebo-controlled trials –
the US Glatiramer Acetate trial [53] and the European/
Canadian MRI study [54], and supported by an initial
small study in 50 patients [55] (Table 1). This latter study
provided the first clinical evidence supporting GA in
RRMS, with 2 years of treatment with GA 20 mg/mL daily
resulting in a significant difference in the proportion
of patients experiencing no relapses versus placebo(56 % vs. 26 %; p = 0.045) [55]. The first pivotal trial, the
US Glatiramer Acetate phase III study, provided clear evi-
dence for the efficacy of GA, demonstrating a significant
29 % reduction favouring GA in annualised relapse rate
(ARR) (0.59 vs. 0.84 for placebo; p = 0.007), supported by
trends in the proportion of relapse-free patients (33.6 %
vs. 27.0 %, respectively), and the median time to first re-
lapse (287 vs. 198 days, respectively), after 2 years of treat-
ment [53] (Table 1). In this study MRI measures were not
used. A second study, the European/Canadian MRI trial,
was planned in order to better define the profile of efficacy
and safety of GA. It provided for the first time MRI
evidence of the beneficial effect of GA; 9 months of ther-
apy resulted in significant differences favouring GA versus
placebo for most endpoints: mean total number of enhan-
cing lesions on T1-weighted images (primary endpoint;
25.96 vs. 36.80; p = 0.003), number of new enhancing
lesions (17.4 vs. 26.0; p < 0.003) and their change of
volume (p < 0.01), number of new lesions detected on T2-
weighted images (9.4 vs. 13.5, respectively; p < 0.003) and
their change of volume (p = 0.001). Moreover, a significant
reduction of the relapse rate was reported in the GA
group versus placebo (33 %; p = 0.012) (Table 1). A later
study that analysed MRI data from the European-
Canadian trial using a fully automated, normalized
method also showed a significant (p = 0.037 at 18 months)
reduction in the development of brain atrophy in the
GA group versus placebo [56]. A noteworthy finding
of the European/Canadian MRI study was a reduction
in severity of tissue disruption in newly-formed le-
sions with GA [48]: the percentage of new lesions
evolving into permanent black holes was significantly
lower in patients treated with GA than in those
receiving placebo at 7 months (18.9 % vs. 26.3 %,
respectively; p = 0.04) and at 8 months (15.6 % vs. 31.4 %,
respectively; p = 0.002) after lesion appearance.
Active comparator-controlled trials GA has been com-
pared head-to-head with high-dose subcutaneous IFN-β1a
or -1b in two double blind trials in patients with RRMS:
REGARD [57] and BECOME [58] (Table 1). Both showed
comparable efficacy between GA and IFN-β1a or -1b.
Moreover in the REGARD trial, GA was found to better
protect against brain-volume loss (–1.07 % vs. –1.24 %;
p = 0.018). These data were confirmed by two trials in
which GA was used as reference comparator. In the BE-
YOND trial [59], two arms receiving IFN-β1b (250 μg and
500 μg) were included, along with a third arm receiving
GA: no significant differences were found between groups
either in the primary endpoint (ARR: 0.33 for IFN-β1b
500 μg, 0.36 for IFN-β1b 250 μg and 0.34 for GA; p = ns
for all comparisons) and in all other clinical outcomes
(Table 1). The CONFIRM trial [60] compared two doses
of dimethyl fumarate versus placebo, again with a third
Table 1 Clinical trials
Study Number of patients Trial length Key outcomes
Placebo-controlled trials
Johnson et al. 1995 [53] 251 randomised 1:1 GA:PBO 2 years Mean relapse rate: GA 1.19 versus PBO 1.68; p = 0.007 (29 % reduction)
(ARR: GA 0.59 versus PBO 0.84)
Comi et al. 2001 [54] 239 randomised 1:1 GA:PBO 9 months Mean reduction in total enhancing lesions GA vs PBO -10.8
(95 % CI -18.0 to -3.7; p = 0.003); 29 % reduction.
Bornstein et al. 1987 [55] 50 randomised 1:1 GA:PBO 2 years Proportion of relapse-free patients GA 56 % vs 26 % PBO; p = 0.045
Active comparator-controlled trials
Mikol et al. 2008 [57]
(REGARD)
764 randomised 1:1 GA:IFNβ-1a 96 weeks No between-group difference in time to first relapse (HR 0.94; 95 % CI
0.74–1.21; p = 0.64)
Cadavid et al. 2009 [58]
(BECOME)
75 randomised 1:1 GA: INF-β1b 2 years Similar median (75th percentile) CAL count per scan in
months 1–12, of 0.58 (2.45) vs 0.63 (2.76)
O’Connor et al. 2009 [59]
(BEYOND)
2447 randomised 2:2:1 250 μg
IFNβ-1b:500 μg IFNβ-1b:GA
3.5 years No between-group differences in relapse risk or EDSS progression
Fox et al. 2012 [60]
(CONFIRM)
Randomised 1:1:1:1 PBO: BG-12
twice daily:BG-12 three times
daily:GA
96 weeks ARR significantly lower with twice-daily BG-12 (0.22), three times-daily
BG-12 (0.20), and GA (0.29) than PBO (0.40) (RR GA 29 %, P = 0.01).
Combination trials
Goodman et al. 2009 [85]
(GLANCE)
110 randomised 1:1 GA + NTZ
versus GA alone
6 months Mean rate of development of new active lesions over the 24-week
study lower with combination therapy (0.03) vs GA alone (0.11;
p = 0.031)
Lindsey et al. 2012 [116]
(CombiRx)
1008 randomised 2:1:1 IFN + GA:
IFN: GA
3 years No difference in ARR between combination group and GA group
(0.12 vs. 0.11). Both combination and GA alone superior to IFN group
(0.16; p = 0.022 for combination group and p = 0.027 for GA group)
Clinically isolated syndrome
Comi et al. 2009 [86]
(PreCISe)
481 randomised 1:1 GA:PBO 36 months GA reduced risk of CDMS by 45 % versus PBO (HR 0.55, 95 % CI
0.40–0.77; p = 0.0005)
95 % CI 95 % confidence interval, ARR Annualised relapse rate, CAL Combined active lesions, CDMS Clinically definite multiple sclerosis, EDSS Expanded disability
status scale, GA Glatiramer acetate, HR Hazard ratio, IFN Interferon, NTZ natalizumab, PBO Placebo, RR Relative risk
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design of the trial did not allow a comparison be-
tween the two active treatments, both drugs proved
to be significantly superior to placebo in all clinical
and MRI outcomes (Table 1). In particular, GA sig-
nificantly reduced the ARR versus placebo by 29 %
(p = 0.01), thus confirming the results of the pivotal
trials in a very large population sample (over 1400
patients). A post hoc subgroup analysis reported nu-
merically similar relapse-related outcomes between
the two dimethyl fumarate arms and the GA arm in
most patient subgroups [61].
A systematic review summarising data from five ran-
domised studies comparing IFN-β with GA in patients
with RRMS confirmed a similar efficacy after 2 years of
treatment [62].
Long-term and real-word data Even with all the limi-
tations of long-term extension studies, due to poten-
tial selection bias, available data suggest that the
efficacy of GA is maintained over time [63–71].
Moreover, there have been no reports of rebound ef-
fect or delayed disease reactivation after treatmentdiscontinuation in extensions of clinical trials or post-
marketing studies [63, 70, 72, 73].
The first follow-up of the US Glatiramer Acetate trial
presented 15-year data [63]. Patients continuing in the
study (100 of the initial 232) showed a reduced ARR
(0.25 ± 0.34 per year vs. 1.12 ± 0.82 at baseline); 57 %
had stable or improved Expanded Disability Status Scale
(EDSS) scores (change ≤0.5 points) and 67 % showed
stable disease, without transitioning to secondary pro-
gressive MS. The most frequently reported reasons for
treatment discontinuation were patient perception of
disease worsening (n = 29), a desire to switch or com-
bine therapies (n = 26) and difficulty, inability, or un-
willingness to adhere to the study protocol (n = 32).
Twenty-year results are now available for the long-
term extension of this study [64]. Of the initial 232
patients, 74 remain in the trial and have been continu-
ously treated for a mean of 19.3 years. Very long-term
use of GA appears to be associated with stable disease
activity (cumulative ARR = 0.2; 24.3 % of patients
remained free of relapse for the entire period) and low
levels of accumulated disability (mean EDSS score 3.1
vs. 2.4 at baseline).
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fers serial long-term MRI data for a large cohort of
patients treated with GA [70]. After the 9-month double-
blind, placebo-controlled phase, all patients entered an
open-label, active treatment phase in which they received
GA 20 mg/mL once daily for a further 9 months, with a
long-term follow-up visit (LTFU) scheduled at least five
years after study entry. Overall, MRI results show that the
effects of GA on MS activity are sustained (number of ac-
tive lesions 0.9 at LTFU vs. 3.4 at baseline; percentage
brain volume change –5.02 vs. baseline). Moreover, MRI
results in the patients that were shifted from placebo to
GA showed a significant reduction of MRI measures of
disease activity, paralleling what was observed in the pa-
tients that received GA from the start. A notable finding is
that the proportion of patients requiring walking aids at
the LTFU was significantly lower (p = 0.034) in the group
that received GA from the start of the study compared
with delayed treatment, suggesting that early treat-
ment may have a positive impact on long-term disease
outcomes.
A 5-year brain MRI retrospective open study provides
some evidence of the efficacy of GA in reducing brain
volume loss [74]: smaller reductions in brain volume
were observed in patients with RRMS treated with sub-
cutaneous GA than with high-dose IFN-β regimens
(percentage change in brain volume –2.27 % vs. –3.21 %;
p < 0.0001).
Various studies report real-world data for GA treat-
ment in RRMS [72, 73, 75, 76], confirming the efficacy
profile of GA observed in the clinical studies. A signifi-
cant impact of the treatment with GA on health-related
quality of life has also been reported [77, 78], with bene-
ficial effects including significant reductions in fatigue
and in days of absence from work.
Controlled studies of MS treatments in children
and adolescents are still lacking, but some published
evidence, albeit retrospective, points to the efficacy of
GA in this population. In an Italian cohort, 14 pa-
tients with a mean age of 13.1 years were treated for
a mean of 5 years or more; these patients had a
reduction in relapse rate, from about 3 per year be-
fore treatment initiation to 0.2–0.4 per year during
the treatment period [79]. A small study of seven patients
with RRMS who had disease onset at 9–16 years of age
and began GA before 18 years of age showed that 24
months of treatment resulted in two of seven patients
remaining relapse free over the study period, and three of
seven patients having stable disability scores as measured
by the EDSS [80].
Switching to glatiramer acetate Several trials have
evaluated switching to GA from other MS therapies for
safety and efficacy reasons [81–83]. For patients notresponding to first line therapies GA can be offered as
an alternative to so-called second line medications if
there are concerns of tolerability/adverse events with the
latter therapies. Most studies describe switches from
IFNβ-1a or -1b to GA, reporting reductions in mean
ARR after switching [81–83]. However, in those situa-
tions when the shift is due to failure of the previous
treatment, results should be interpreted with caution be-
cause the regression to the mean phenomenon is a
major concern. Therefore, randomised, controlled trials
are needed to confirm these results.
Combination treatment trials Two important combin-
ation therapy trials are the CombiRx trial [84] and the
GLANCE trial [85] (Table 1). In CombiRx, patients were
randomised to GA 20 mg/mL once daily plus IFN-β1a 30
μg once weekly or to monotherapy with one of these med-
ications plus placebo for 3 years. For the primary outcome
of ARR, the combination therapy was significantly super-
ior to IFN-β, reducing the relapse rate by 25 % (p = 0.022),
while there was no significant difference between the
combination therapy and GA. It should be noted that the
study design allowed for the first time a comparison be-
tween intramuscular IFN-β and GA, with GA resulting
superior (relapse rate reduction by 31 % compared with
IFN-β; p = 0.027). The GLANCE study compared com-
bination therapy with GA 20 mg/mL once daily plus
intravenous natalizumab 300 mg every 4 weeks versus
monotherapy with GA 20 mg/mL once daily plus placebo
every 4 weeks. At 24 weeks, the combination therapy was
superior on major MRI disease activity measures.
In clinically isolated syndrome
Early treatment with GA in patients with CIS has been
shown to delay onset of CDMS in the placebo-controlled
study PreCISe [86] (Table 1) and during its subsequent
open-label extension period [87]. The study enrolled 481
patients with one unifocal neurological event and a posi-
tive MRI scan (defined as the presence of at least two
cerebral lesions ≥6 mm in diameter on T2-weighted im-
ages). Patients were randomised to GA 20 mg/mL once
daily or placebo for up to 36 months or until conversion
to MS. GA was associated with a 45 % reduction in risk of
conversion to MS (primary endpoint; p = 0.0005) and a
delay in the time to conversion compared with placebo
(336 days vs. 722 days, respectively). GA was associated
with a 58 % reduction in number of new T2 lesions and a
smaller volume of T2 lesions. During the extension phase
(total 5 years’ duration) the efficacy of GA was sustained,
with a 41 % reduction in risk of conversion to MS in those
treated with GA from the start compared with delayed
treatment; in the GA group, there was a delay of 972 days
before conversion to MS, a 42 % reduction in new T2 le-
sions per year (p < 0.0001) and a 22 % reduction in T2-
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tients treated with GA from study entry showed a signifi-
cant 28 % reduction (p = 0.0209) in brain volume loss
compared with patients initially randomised to placebo,
confirming the neuroprotective effects of GA. This is
the first trial to demonstrate that early treatment with
GA reduces brain atrophy versus delayed treatment in
this setting.
In progressive forms of multiple sclerosis
GA was assessed in primary progressive forms of MS,
with negative results. The PROMiSe study [88] was a
randomised, double-blind, placebo-controlled, multicen-
tre, international study that investigated the effect of GA
on disability progression in 943 patients with progressive
MS. After 3 years of treatment, the time to sustained
accumulated disability was similar between GA- and
placebo-treated patients (hazard ratio [HR] 0.87; 95 %
CI 0.71 to 1.07; p = 0.1753). A post hoc analysis showed
a possible effect in slowing clinical progression in male
patients (HR 0.71; 95 % CI 0.53 to 0.95; p = 0.0193) [88],
but a subsequent analysis of these results did not dem-
onstrate an impact of gender on the efficacy of GA [89].
An additional study investigating metabolite ratios as de-
termined by MRI in a subset of 58 patients from the
PROMISe study showed no difference between the GA
and placebo groups [90]. However, it should be noted
that the PROMISe study was terminated early due to
lack of effect, and that the low rate of disability progres-
sion and the high rate of premature discontinuations led
to a decrease in power of the study, hampering the de-
termination of a treatment effect [88].
Three times weekly formulation
The first trial to evaluate a high-dose regimen of GA was
the phase III FORTE study [51] that compared the 40 mg/
mL once daily dose with the standard 20 mg/mL once
daily dose in patients with RRMS. Both doses showed
similar effects on efficacy measures and no difference in
the safety profile. Post-hoc analyses revealed potential
benefits of the 40 mg/mL dose in some subgroups (for ex-
ample, in the “frequent MRI cohort” patients treated with
40 mg/mL showed a slight numerical advantage in the re-
duction of the mean number of gadolinium-enhancing le-
sions at various timepoints vs. baseline). After this study
the development of the high-dose once daily regimen was
discontinued, but it provided a starting point for subse-
quent research on the high-dose, lower-frequency regimen
(40 mg/mL three times weekly).
The efficacy of subcutaneous GA 40 mg/mL three times
weekly in patients with RRMS was shown in the 1-year,
double blind, placebo-controlled GALA study, involving
about 1400 patients [8]. Significant reductions com-
pared with placebo in relapse rate (34.0 %; p < 0.0001),cumulative number of gadolinium-enhancing T1 le-
sions (44.8 %; p < 0.0001) and new or enlarged T2 le-
sions (34.7 %; p < 0.0001) were reported; the numerical
values of these parameters were very similar to those
observed in the pivotal studies with the 20 mg/mL once
daily dose. Three-year results of the open-label extension
of the GALA study demonstrated sustained efficacy on
ARR and MRI parameters of disease activity [91]. Patients
switched from placebo to GA after the double blind phase
reported significant gains in efficacy, but those treated
with GA from study entry showed a significantly lower re-
lapse rate (ARR 0.23 vs 0.30, respectively, p = 0.0052) and
significantly fewer enhancing T1 lesions and new or en-
larged T2 lesions (RR = 0.660, p = 0.0005 for T1; RR =
0.680, p < 0.0001 for T2) compared with patients with
delayed treatment.
An important finding from a recent post hoc MRI ana-
lysis of data from the GALA study is that GA 40 mg/mL
three times weekly (cumulative weekly dose of 120 mg)
shares the ability of the standard formulation (cumu-
lative weekly dose of 140 mg) to reduce conversion of
new active lesions into black holes, markers of perman-
ent damage and disability progression, with a significant
24 % reduction compared with placebo (p = 0.006) in
the odds of conversion from new lesions at month 6 to
black holes at month 12 [49].
In the absence of head-to-head studies comparing GA
20 mg/mL once daily and 40 mg/mL three times weekly,
indirect comparisons have also shown very similar effi-
cacy of the two doses [92, 93].
On the same lines, the GLACIER study, in which pa-
tients were asked to report the personal experience of
shifting from the 20 mg/mL once daily dose to the 40 mg/
mL three times weekly dose, demonstrated a favourable
convenience profile and patient satisfaction when convert-
ing from the once-daily formulation [94].
Safety
After 20 years’ continuous clinical use and more than 2
million patient-years’ exposure, the safety profile of GA
is well established. No evidence of any association of GA
with immunosuppression or with malignant and auto-
immune disease has been reported after 10 and 15 years
follow-up [63, 65]. GA was not associated with psychi-
atric or mood disorders and in some studies a significant
improvement in fatigue was observed, even in patients
switching from other DMTs [78]. In a study of patients
with RRMS and spasticity, switching from IFN-β to GA
improved spasm frequency, muscle tone and pain after 3
months of treatment; these improvements were main-
tained over 6 months of treatment with GA [95]. A few
cases of hepatotoxicity during treatment with GA have
recently been reported [96–98], with no such cases re-
ported in clinical trials, hence it is unclear at present if
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noted, though, that because some of the patients report-
ing this AE had concurrent autoimmune conditions, it is
impossible to disentangle the potential contribution of
GA treatment and the underlying condition to hepato-
toxicity. IgE-mediated allergic reactions have also been
described [99, 100].
Both formulations of GA appear equivalent from the
safety standpoint [64, 91, 94]. In the GALA study AEs as-
sociated with administration of GA 40 mg/mL three times
a week were found to be consistent with the known safety
profile of GA 20 mg/mL once daily. Moreover, no new
AEs emerged during treatment with high-dose GA [8, 91].
At present there are no controlled studies of DMTs in
children and adolescents with MS, but published evidence,
mostly retrospective studies, support a similar safety pro-
file of GA in this population [79, 80]. GA, along with IFN-
β, has been recommended as the standard treatment for
paediatric RRMS in two position papers, one produced by
European experts [101] and the other one by the Inter-
national paediatric MS Study [102]. Since paediatric onset
MS is characterized by high disease burden, early treat-
ment, although off-label, should be promptly started after
confirmation of the diagnosis. The favourable tolerability
profile of GA should be considered when making a thera-
peutic choice [101, 102].
No limitations to concomitant administration of GA
and other drugs have been identified; the medication is
not linked to blood test abnormalities that require
monitoring.
Pregnancy
Animal reproduction studies have failed to demonstrate a
risk of GA treatment to the foetus, and post-marketing
studies support the absence of foetal toxicity [103–108].
For these reasons GA has been classified as FDA Class B
during pregnancy [109]. Most of the other drugs approved
for the treatment of MS are categorized by the FDA as
Class C, with the exception of mitoxantrone, classified as
Class D (positive evidence of human foetal risk), and teri-
flunomide, classified as Class X (foetal toxicity) [104, 109].
GA can be continued right up until conception, unlike
other DMTs for which a washout period is recommended
prior to trying to conceive [104]. GA may also be used as
bridging therapy in women planning a pregnancy who are
receiving treatments requiring a washout period, if it
exposes women to the risk of MS reactivation, and of-
fers some advantages in women risking unplanned
pregnancies.
While it is currently recommended that, as for any
other DMT, GA should be discontinued after confirmed
evidence of pregnancy and until childbirth, available evi-
dence suggests GA could be continued at least through-
out the first trimester, while further continuation of GAtreatment may be assessed on a case-by-case basis [104].
An Italian retrospective study showed that the mother’s
exposure to GA when the drug was suspended within 4
weeks from conception was not associated with an in-
creased frequency of spontaneous abortion nor with
other negative pregnancy and foetal outcomes compared
with women in whom the medication was suspended 4
weeks or more from conception, or who were untreated
[107]. These findings confirm those of a previous obser-
vational study [106] suggesting that GA and the IFNs do
not represent a significant risk for prenatal developmen-
tal toxicity. Relapse rate decreases during pregnancy,
with a well-known increase in the first three months
after childbirth [110] that sometimes requires second-
line therapy to be controlled [103–105].
Tolerability
The tolerability of GA 20 mg/mL once daily has con-
sistently been reported as good versus both placebo
and active treatment in the previously mentioned clin-
ical trials [54, 57, 59, 86], and the nature and frequency
of treatment-related AEs were similar between short-
and long-term treatment periods [63–65, 67]. The most
common (>1/10) treatment-related AEs are transient
injection-site reactions, occurring occasionally in about
two thirds of patients [7]. These include injection site
bruising, erythema, pain, pruritus and induration. Rarer
cases of localized lipoatrophy and skin necrosis at injection
sites have been reported during post-marketing [111, 112].
One peculiar injection-related tolerability issue with GA is
the occurrence of immediate post-injection reactions
(IPIR) that present immediately or a few minutes after the
injection, consisting in flushing, chest tightness, palpita-
tion, dyspnoea and intense anxiety. The crisis resolves
spontaneously in a few minutes [53]. These reactions are
unpredictable, affecting about 15 % of patients and seldom
recurring more than once. The intensity of the reaction is
not connected to any real risk to patients.
The tolerability of GA 40 mg/mL three times weekly
has been shown to be similar to that of the 20 mg/mL
once-daily formulation [8, 91]. Importantly, in the GLA-
CIER study [94], three times weekly GA was found to be
better tolerated than the once-daily formulation in terms
of injection-related adverse events (IRAEs): the adjusted
mean annualized rate of IRAEs was reduced by 50 % in
patients receiving the new formulation (35.3 events per
year vs. 70.4 events per year, respectively; p = 0.0006),
while the rate of moderate/severe events was reduced by
60 % (0.9 events per year vs. 2.2 events per year, respect-
ively; p = 0.0021). Furthermore, treatment convenience,
as measured by the Treatment Satisfaction Question-
naire for Medication-9 (TSQM-9) convenience subscale,
was improved for patients switching from GA 20 mg/
mL once daily to the three times weekly formulation
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GLACIER study confirm the safety profile of the 40 mg/
mL three times weekly formulation, in terms of both
IRAEs and convenience [113].Conclusions
The availability of multiple drugs has totally changed the
scenario of MS treatment. Treatment choices became
much more complicated and decisions should be based
on the combination of the efficacy and safety profiles.
From this point of view GA associates a favourable effi-
cacy profile, confirmed by more than 20 years of clinical
use, with an excellent safety and tolerability profile. The
burden of daily injections has been recently reduced by
the availability of the new 40 mg/mL three times a week
formulation, which has been shown to share the same effi-
cacy of the 20 mg/mL once daily formulation, but with
obvious advantages in terms of patient convenience.
GA has been classified as a first-line drug for the treat-
ment of RRMS in Europe, with a clear indication both in
naïve patients and in patients who discontinue other ther-
apies for safety or tolerability issues. The recent evidence of
the importance of personalized treatment implies that the
assessment of the individual prognostic profile should drive
treatment decisions, at the same time considering also pa-
tients’ preference and convenience. Patients with a good
prognostic profile as indicated by low disease activity – re-
vealed by low brain lesion burden and few or absent active
lesions at the time of treatment onset – may have a high
probability of responding to first-line therapies, including
GA. On the contrary, patients with very active disease in
the early phases tend to require an induction approach to
obtain a positive response to treatment.
Considering the choice among first-line therapies, GA
offers an obvious advantage in young, potentially fertile
women for the favourable safety profile in this popula-
tion, as discussed above [107]. Patients with CIS are also
expected to benefit from GA, given the evidence of effi-
cacy in such patients, supported by extension studies
showing clear protection from brain atrophy [86, 87].
Another possible use of GA is as maintenance treatment
in patients who start with an induction approach be-
cause of a negative prognostic profile. Induction therapy
has often the advantage of “reshaping” the immune sys-
tem, which can then be maintained by GA [114, 115].
The classification of MS clinical courses [2] defines the
importance of disease activity not only in RRMS, but also
in patients with a progressive disease course. The presence
of disease activity represents a clear target for DMTs.
Among them, the use of GA should be considered because
of the long-term safety and absence of negative impact on
spasticity, a frequent AE of IFN-β treatment in this popula-
tion. It should be noted, however, that conclusive data fromclinical trials demonstrating the efficacy of GA in these pa-
tients are currently lacking.
We anticipate that the new 40 mg/mL three times
weekly regimen might increase compliance and adher-
ence. Therefore it is recommended that, in all consenting
patients currently treated with the once daily formulation,
the switch to the new formulation should be considered.
An early start of GA treatment should be considered in
the light of data on brain atrophy from the PreCISe study
[87]: there was a significant (–28 %; p = 0.0209) difference
when comparing early GA treatment versus delayed GA
treatment.
In conclusion, clinical trials and real-life studies have
consistently shown the efficacy and safety of both for-
mulations of GA in the first-line treatment of patients
with RRMS and for delaying the onset of clinically defin-
ite MS in patients with CIS. Overall, data suggest that
while many types of patients can be expected to benefit
from GA, the “ideal” subject would be one with RR dis-
ease or newly-diagnosed, young and active, wanting to
lead a normal life. The use of GA for more than two
decades shows a reassuring safety profile and optimal
tolerability. The major concern may be the frequency of
administration, an issue that the new formulation can
be expected to minimize, contributing to the use of this
drug. Besides patient convenience, the fact that no
complex clinical monitoring is required during treat-
ment clearly represents another strong point of the
clinical use of GA.
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